NAD+ Dosage and Side Effects: What to Know Before Your First Session

The NAD+ dosage question is what most people search for after reading about the biology and deciding they want to try supplementation. The honest answer is that no clinical trial has established a single optimal dose for any specific outcome. What the trials have established is a safety envelope — a range of doses tested in humans with a consistently favorable tolerability record. Understanding that envelope, and how dosage requirements differ across oral supplements, subcutaneous injections, and IV infusions, gives you the context for a meaningful conversation with a licensed provider before your first session. The 2025 Zhang meta-analysis of 12 NMN RCTs (PubMed 39116016) is the most comprehensive aggregate safety assessment for oral NMN supplementation in adults. For a broader overview of how NAD+ fits into a longevity protocol, the Peptides and Healthy Aging article covers where it sits alongside other approaches.

NAD+ Dosage for Oral Supplements: NMN and NR

Oral NAD+ precursors carry the deepest human dosage and safety data of any delivery route. More than 30 published human clinical trials have studied NMN and NR at various doses. A 2026 safety review summarizing that evidence concluded that NAD+ and its precursors show a low incidence of side effects across the studied dose range, with the most common complaints being mild and gastrointestinal in nature.

NMN: What Clinical Trials Have Actually Tested

NMN (nicotinamide mononucleotide) has been studied at doses from 100 mg per day up to 1,250 mg per day in published human trials. The most common NAD+ dosage used across studies is 250 mg per day. A Japanese safety study in the Endocrine Journal (Irie et al. 2020) tested a single oral dose of 500 mg in healthy men and reported no clinically significant adverse effects. Higher doses have also been evaluated: Harvard Medical School tested 1,000 mg twice daily for 14 days with no serious adverse events reported. A Frontiers in Nutrition study reached 1,200 mg per day without serious adverse effects. The GeroScience multicenter trial found that 600 mg per day produced meaningful NAD+ elevation and physical performance signals in older adults, making 500 to 600 mg the most frequently cited practical reference point.

No liver toxicity has been documented in any published NMN clinical trial. Zero serious adverse events have been attributed to NMN supplementation across the published evidence base.

NR: What Clinical Trials Have Actually Tested

NR (nicotinamide riboside) has a longer clinical history than NMN. Human trials have studied NR at doses from 100 mg to 2,000 mg per day, with 2,000 mg established as the maximum safe daily dose in the Dollerup et al. controlled trial. The NR-SAFE safety trial in patients with Parkinson’s disease pushed the NAD+ dosage to 3,000 mg per day for 30 days and found NR well tolerated without moderate or severe adverse events, supporting a possible extension of the dose range in future trials. Across 20-plus published human trials, no serious adverse events have been attributed to NR. NR does not produce the flushing that is commonly associated with niacin (vitamin B3) because it metabolizes through a different enzymatic pathway.

NAD+ Dosage for Subcutaneous Injections

Subcutaneous NAD+ injections use doses of 25 to 100 mg per injection, administered under the skin rather than into a vein. This lower NAD+ dosage range reflects two factors: the more direct absorption pathway that bypasses digestion, and the lower side effect threshold achievable with subcutaneous delivery compared to IV. At doses below 100 mg via the subcutaneous route, the infusion-related reactions common with IV NAD+ are largely avoided.

No controlled trial has established an optimal subcutaneous dosing protocol. Clinical protocols are based on provider experience and pharmacokinetic reasoning. A licensed provider prescribing subcutaneous NAD+ will select a starting dose and frequency based on the clinical picture, health history, and response to initial sessions, not on an evidence-based dosing table that does not yet exist.

NAD+ Dosage for IV Infusions

IV NAD+ therapy uses doses of 250 to 1,000 mg per session, administered over 2 to 4 hours via slow IV drip in a clinical setting. Unlike oral supplementation, IV dosing is constrained not primarily by safety concerns but by tolerability during the infusion itself. Higher doses or faster infusion rates produce the characteristic infusion reactions (nausea, flushing, chest tightness, cramping) that represent the most significant practical limitation of IV NAD+ therapy. These reactions are rate-dependent and typically resolve when the infusion is slowed.

NAD+ Side Effects: What 30+ Clinical Trials Report

The side effect profile of oral NAD+ precursors is one of the most favorable of any supplement category studied at comparable doses and trial durations. A 2026 safety review summarizing the evidence concluded that NAD+ and its precursors show a low incidence of side effects, with the most common complaints being mild and gastrointestinal.

Oral NMN and NR Side Effects

Across more than 30 published human trials, zero serious adverse events have been attributed to either NMN or NR. The most commonly reported side effects at higher doses are mild gastrointestinal symptoms including nausea, loose stools, and stomach discomfort. These are dose-dependent and tend to reduce or resolve when the dose is lowered or the supplement is taken with food. Skin flushing, commonly associated with niacin, is rare with NMN and NR because they metabolize through a different pathway. No liver toxicity has been documented in any published NMN trial.

One distinction worth knowing if you have taken niacin: the flushing and tingling skin reaction associated with high-dose vitamin B3 therapy is not expected with NMN or NR. All three are vitamin B3 variants but are metabolized through different enzymatic pathways, and niacin’s characteristic flush is not observed with NR or NMN in any published clinical trial.

IV NAD+ Side Effects: More Significant and Rate-Dependent

The IV delivery route carries a considerably more significant side effect profile than oral supplementation. IV NAD+ commonly produces nausea, facial flushing, headache, chest tightness or pressure, abdominal cramping, and a general malaise during the infusion. These effects are directly related to the concentration of extracellular NAD+ produced by rapid IV delivery, not to toxicity of the compound itself.

The side effects are rate-dependent: more intense at higher doses given faster, less intense at lower doses given slowly. Slowing the infusion rate is the standard clinical response and resolves reactions in most cases. This is why IV NAD+ therapy requires 2 to 4 hours per session. A well-run IV session at a reputable clinic starts at a conservative rate and adjusts based on the patient’s response during the first portion of the infusion. The comparison of delivery methods including the full side effect profiles is covered in the companion article on NAD+ IV Therapy vs Injections vs Oral.

Who Should Use Caution With NAD+ Supplementation

The human clinical trial data shows a favorable safety profile for oral NAD+ precursors in healthy adults. Several populations warrant more careful evaluation before initiating any NAD+ protocol.

Active malignancy: NAD+ is required for PARP enzyme activity and cellular proliferation. The theoretical concern that NAD+ elevation could support cancer cell metabolism is not confirmed as a clinical risk at supplement doses in the published evidence, but it is a reason that active malignancy history requires physician evaluation before any NAD+ protocol, across all delivery routes.

Cardiovascular conditions: IV NAD+ therapy’s transient cardiovascular symptoms, specifically chest tightness and blood pressure changes, make it inappropriate for patients with established cardiovascular disease without careful provider assessment. Oral supplementation does not carry the same acute cardiovascular concern.

Patients on concurrent medications: NMN and NR are metabolized through nicotinamide pathways that interact with some medications. PARP inhibitors used in oncology are one example where NAD+ pathway interaction may be clinically relevant. A complete medication review with a provider before starting any NAD+ supplement is appropriate standard practice.

The pre-evaluation framework that applies to any supplement or peptide protocol is covered in the Lab Checklist Before Peptide Therapy article. For an understanding of what the first clinical evaluation process looks like, the First Peptide Therapy Consultation guide walks through the process step by step.